eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast

Stock Information for eXoZymes Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About eXoZymes Inc.

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
eXoZymes Inc. Announces Closing of $6 Million Public Offering
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.